Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS G12C -Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis.
Vincenzo FormicaCristina MorelliVeronica ConcaMaria Alessandra CalegariJessica LucchettiEmanuela Dell'AquilaMarta SchirripaMarco MessinaLisa SalvatoreFederica Lo PrinziGiovanni DimaGiovanni TrovatoSilvia RiondinoMario RoselliFerdinandos SkoulidisHendrik-Tobias ArkenauChiara CremoliniPublished in: Cancers (2023)
-mutated mCRC patients and should be preferred over oxaliplatin. These findings should also be considered when investigating chemotherapy plus targeted agent combinations.
Keyphrases
- metastatic colorectal cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- wild type
- peritoneal dialysis
- clinical trial
- randomized controlled trial
- squamous cell carcinoma
- locally advanced
- study protocol
- prognostic factors
- radiation therapy
- cross sectional
- patient reported outcomes
- drug delivery